CA2390531A1 - Azetidines ¬(indol-3-yl)-cycloalkyl|-3-substituees pour le traitement de troubles du systeme nerveux central - Google Patents

Azetidines ¬(indol-3-yl)-cycloalkyl|-3-substituees pour le traitement de troubles du systeme nerveux central Download PDF

Info

Publication number
CA2390531A1
CA2390531A1 CA002390531A CA2390531A CA2390531A1 CA 2390531 A1 CA2390531 A1 CA 2390531A1 CA 002390531 A CA002390531 A CA 002390531A CA 2390531 A CA2390531 A CA 2390531A CA 2390531 A1 CA2390531 A1 CA 2390531A1
Authority
CA
Canada
Prior art keywords
carbon atoms
compound
pharmaceutically acceptable
acceptable salt
azetidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002390531A
Other languages
English (en)
Inventor
Magda Asselin
Richard Eric Mewshaw
John Watson Ellingboe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2390531A1 publication Critical patent/CA2390531A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des composés, des compositions pharmaceutiques ainsi que toutes leurs formes cristallines ou l'un de leurs sels pharmaceutiquement acceptables et des modalités d'utilisation de ces composés pour le traitement de troubles du système nerveux central tels que l'anxiété et la dépression. Ces composés sont représentés par la formule générale (I). Dans cette formule, X est N-R, O, S(O)¿m?; m vaut 0 à 2; n vaut 0 à 4. Ar est un groupe aryle en C¿6?-C¿12? éventuellement substitué par 1 à 3 groupes R¿3?, ou un groupe hérétoaryle en C¿4?-C¿10? éventuellement substitué par 1 à 3 groupes R¿3?. R et R¿2? sont indépendamment H, chaîne alkyle droite en C¿1?-C¿6?, alkyle ramifié en C¿3?-C¿6?, cycloalkyle en C¿3?-C¿6?, alcoxycarbonyle en C¿1?-C¿6?, alkylcarbonyle en C¿1?-C¿6?, aminocarbonyle, ou alkylaminocarbonyle en C¿1?-C¿4?. R¿1? et R¿3? sont indépendamment H, chaîne alkyle droite en C¿1?-C¿4?, alkyle ramifié en C¿3?-C¿6?, cycloalkyle en C¿3?-C¿8?, halo, groupe alcoxy en C¿1?-C¿4?, haloalkyle en C¿1?-C¿4?, OH, nitro, amino, sulfonyle, CN, carboxy, alkoxycarbonyle en C¿1?-C¿4?, alkylcarbonyle en C¿1?-C¿4?, aminocarbonyle, ou alkylaminocarbonyle en C¿1?-C¿4?.
CA002390531A 1999-11-08 2000-10-31 Azetidines ¬(indol-3-yl)-cycloalkyl|-3-substituees pour le traitement de troubles du systeme nerveux central Abandoned CA2390531A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43611999A 1999-11-08 1999-11-08
US09/436,119 1999-11-08
PCT/US2000/029954 WO2001034598A1 (fr) 1999-11-08 2000-10-31 Azetidines [(indol-3-yl)-cycloalkyl]-3-substituees pour le traitement de troubles du systeme nerveux central

Publications (1)

Publication Number Publication Date
CA2390531A1 true CA2390531A1 (fr) 2001-05-17

Family

ID=23731187

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002390531A Abandoned CA2390531A1 (fr) 1999-11-08 2000-10-31 Azetidines ¬(indol-3-yl)-cycloalkyl|-3-substituees pour le traitement de troubles du systeme nerveux central

Country Status (8)

Country Link
EP (1) EP1228065A1 (fr)
JP (1) JP2003513970A (fr)
CN (1) CN1414962A (fr)
AU (1) AU1446601A (fr)
BR (1) BR0015401A (fr)
CA (1) CA2390531A1 (fr)
MX (1) MXPA02004555A (fr)
WO (1) WO2001034598A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070021404A1 (en) * 2003-06-24 2007-01-25 Dan Peters Novel aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
PE20060373A1 (es) 2004-06-24 2006-04-29 Smithkline Beecham Corp Derivados 3-piperidinil-7-carboxamida-indazol como inhibidores de la actividad cinasa de ikk2
PE20060748A1 (es) 2004-09-21 2006-10-01 Smithkline Beecham Corp Derivados de indolcarboxamida como inhibidores de quinasa ikk2
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
JP5782381B2 (ja) 2008-12-10 2015-09-24 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ Ｃｃｒ２の４−アゼチジニル−１−ヘテロアリール−シクロヘキサノールアンタゴニスト
WO2010102968A1 (fr) 2009-03-10 2010-09-16 Glaxo Group Limited Dérivés d'indole comme inhibiteurs de ikk2
US8324186B2 (en) 2009-04-17 2012-12-04 Janssen Pharmaceutica N.V. 4-azetidinyl-1-heteroatom linked-cyclohexane antagonists of CCR2
WO2010121046A1 (fr) 2009-04-17 2010-10-21 Janssen Pharmaceutica Nv Antagonistes de ccr2 a base de 4-azetidinyl-1-phenyl-cyclohexane
TW201211027A (en) * 2010-06-09 2012-03-16 Janssen Pharmaceutica Nv Cyclohexyl-azetidinyl antagonists of CCR2
EP2582692B1 (fr) 2010-06-17 2015-07-22 Janssen Pharmaceutica NV Cyclohexyl-azetidines commme inhibiteurs de la ccr2
CA3027500A1 (fr) * 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Inhibiteurs de cxcr4 et leurs utilisations
JP7054529B2 (ja) 2016-06-21 2022-04-14 エックス４ ファーマシューティカルズ， インコーポレイテッド Ｃｘｃｒ４阻害剤およびその使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9401436D0 (en) * 1994-01-26 1994-03-23 Wellcome Found Therapeutic heterocyclic compounds
ES2182509T3 (es) * 1998-04-08 2003-03-01 Wyeth Corp Derivados de n-ariloxietilamina para el tratamiento de la depresion.
ATE269303T1 (de) * 1999-01-07 2004-07-15 Wyeth Corp Arylpiperazinyl-cyclohexyl indolderivate zur behandlung von depressionen

Also Published As

Publication number Publication date
WO2001034598A1 (fr) 2001-05-17
MXPA02004555A (es) 2004-09-10
CN1414962A (zh) 2003-04-30
EP1228065A1 (fr) 2002-08-07
JP2003513970A (ja) 2003-04-15
BR0015401A (pt) 2002-07-02
AU1446601A (en) 2001-06-06

Similar Documents

Publication Publication Date Title
US6245799B1 (en) [(Indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders
US7049335B2 (en) 3-azabicyclo[3.1.0]hexane derivatives
EP1551803B1 (fr) Derives azabicyclo utilises comme antagonistes des recepteur muscariniques
CA2390531A1 (fr) Azetidines ¬(indol-3-yl)-cycloalkyl|-3-substituees pour le traitement de troubles du systeme nerveux central
CZ20011760A3 (cs) Pyrrolidinové deriváty jako antagonisty CCR-3 receptorů
EP2167083B1 (fr) 1- hétéroaryl-3-azabicyclo[3.1.0]hexanes, leurs méthodes de préparation et leur utilisation comme médicaments
JP2010505851A (ja) ヒスタミン−３アンタゴニストとしてのｎ−置換−アザシクリルアミン
EP1581522B1 (fr) Derives de flavaxate comme antagonistes de recepteurs muscariniques
US20070010568A1 (en) Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
AU2003214535B2 (en) Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
CA2511726A1 (fr) Derives de xanthine utilise en tant qu'antagonistes des recepteurs muscariniques
US6066637A (en) Indolyl derivatives as serotonergic agents
US20070135508A1 (en) 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
CA2074727A1 (fr) Derives indole, leur preparation et leur utilisation
CA2330437A1 (fr) Derives d'indolyle en tant qu'agents serotoninergiques
CA2390530A1 (fr) Amines de n-aryl-(homopiperazinyl)-cyclohexyl, utilisees comme transporteurs de 5-ht
US6337326B1 (en) N-aryl-(homopiperazinyl)-cyclohexyl amines
RU2139287C1 (ru) Соединения 3-замещенного 1-арилиндола и фармацевтическая композиция на их основе
JPH0948776A (ja) ピリミジニルピラゾール誘導体
MXPA00010456A (es) Agentes serotonergicos

Legal Events

Date Code Title Description
FZDE Dead